# Maciej Krzakowski

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maciej-krzakowski/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,752 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 116 |
| Last Known Institution | National Institute of Oncology |
| OpenAlex ID | https://openalex.org/A5073572288 |
| ORCID iD | https://orcid.org/0000-0003-3324-0900 |
| Works | 574 |

## Researcher papers

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial](https://scholariq.org/papers/docetaxel-plus-nintedanib-versus-docetaxel-plus-placebo-in-patients-with/)
- [Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study](https://scholariq.org/papers/overall-survival-improvement-in-patients-with-lung-cancer-and-bone-metastases/)
- [Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-dacomitinib-pf-00299804-an-irreversible-pan-human/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [National Institute of Oncology](https://scholariq.org/institutions/national-institute-of-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.